Summary Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to treatment with aminoglutethimide plus cortisone acetate. All had relapsed from or failed to respond to primary endocrine treatment with orchidectomy or stilboestrol. Nineteen patients (48%) showed subjective response, in most cases relief of bone pain. Side effects limited treatment in only 3 patients. We conclude that aminoglutethimide plus cortisone acetate is a useful addition to the treatment available for this difficult group of patients. The mechanism by which this treatment has a beneficial effect remains unclear.
Eighty-five per cent of patients with advanced adenocarcinoma of the prostate respond to treatment by orchidectomy or stilboestrol, but all eventually relapse, most of them with disabling pain from bony metastases. Treatment of these patients, many of them elderly and in poor general condition, is a difficult problem (Lancet, 1980) . The response of some patients to cortisone alone (Miller & Hinman, 1954) or to bilateral adrenalectomy (Mahoney & Harrison, 1972; Hendry, 1974) suggests that in some cases the tumour may retain sensitivity to residual adrenal androgens. Aminoglutethimide is an inhibitor of several enzymes involved in adrenal steroid synthesis (Dexter et al., 1967) and in prostaglandin metabolism (Harris et al., 1983c) . The combination of aminoglutethimide and hydrocortisone had previously been reported both to reduce circulating levels of adrenal androgen and, in small numbers of patients, to induce responses in hormone-relapsed advanced prostatic cancer (Robinson et al., 1974; Sanford et al., 1976) .
The primary clinical goal in these patients is relief of symptoms rather than objective evidence of shrinkage of tumour masses. We therefore evaluated subjective response to aminoglutethimide plus cortisone acetate in terms of pain, analgesic requirement, performance status, and the side effects of treatment in a series of 40 patients. We also measured circulating adrenal androgens before and during treatment to examine the relationship between suppression of androgen levels and clinical response.
Patients and methods

Patients
This was a multi-centre study. The Hormone studies Ten ml of serum was taken before treatment and at each visit, separated and stored at -20°C. Hormone assays were carried out in 2 batches at the end of the study. Dehydroepiandrosterone sulphate (DHA-S) , A4 androstenedione (Dowsett et al., 1984) and sex hormone binding globulin (SHBG) (Iqbal & Johnson, 1977) were measured according to previously described methodology. Testosterone was measured using the EIR-RIA kit which employs a 1251-testosterone tracer and has a sensitivity of 0.10 nmol -1. Within and between assay coefficients of variation (CV) were 5.8% and 9.3% respectively at a serum concentration of 2 nmol 1-l. 5a-dihydrotesterone (Sa DHT) was measured by radioimmunoassay after oxidation of testosterone to a glycol of insignificant cross-reactivity. The sensitivity of the assay was 0.10 nmol 1-1 and the within and between assay CVs were 6.2% and 11.1% respectively at a serum concentration of 0.7 nmol I1.
Results
Nineteen out of 40 patients obtained a subjective response. The magnitude of the response is shown in Table IV . Of 33 patients in whom bone pain was the dominant symptom, 17 (51%) obtained benefit by the same criteria: an improvement of pain assessment score by at least 2 points, lasting for at least 4 weeks. None of the 4 patients with measurable soft-tissue disease responded by a sustained reduction of more than 50% in the area of the lesions. post= average of all samples between 1 and 3 months. R = responders. NR = non-responders. dotted line =detection limit of assay. * = 3 patients classified as having objectively stable disease by NPCP criteria (see Table V ). living at home. The dose regime which we used was designed to minimise the side effects which are most commonly seen within the first week of treatment. Both the onset of subjective response and the timing of the endocrine changes (not shown) indicate that the major effects of treatment were already apparent within the first two weeks; that is, on the lowest dose of 250 mg aminoglutethimide twice daily. This result must be interpreted with caution, both because aminoglutethimide has been reported to induce its own metabolism (Murray et al., 1979) , and because the role of aminoglutethimide in producing the clinical response is still unclear (see below). Nevertheless, as in the treatment of breast cancer (Harris et al., 1983a (Harris et al., , 1983b it suggests that the lower dose of aminoglutethimide may be sufficient for therapeutic effect, and higher doses may merely increase the incidence of side effects.
Although the regime of aminoglutethimide plus corticosteroid is effective, it is not clear how it works. Inhibition of adrenal androgen production provided the original rationale, in view of the responses obtained by surgical adrenalectomy (Mahoney & Harrison, 1972; Hendry, 1974) . Worgul et al. (1983) nevertheless questioned whether the decreases in androgen levels with treatment in their patients were necessarily of biological significance, and the same question is posed by our finding that the measured effects on androgen levels were no different between responders and non-responders. This might be explained by different androgen sensitivity of responsive and non-responsive tumours.
Alternatively, the effects of aminoglutethimide might be due to inhibition of oestrogen production by inhibition of the aromatase enzyme (Harris et al., 1983b; Santen et al., 1978 (Glick et al., 1982) and the anti-androgen cyproterone acetate, chemotherapy (Schmidt, 1980; Citrin et al., 1983) , hemibody irradiation (Epstein et al., 1979) , and pituitary ablation (Fitzpatrick et al., 1980; Fergusson & Hendry, 1971; Tindall et al., 1979 Geigy.
